Literature DB >> 10921549

Volume expansion using pentastarch does not change gastric-arterial CO2 gradient or gastric intramucosal pH in patients who have sepsis syndrome.

D M Forrest1, F Baigorri, D R Chittock, J J Spinelli, J A Russell.   

Abstract

OBJECTIVE: In hypovolemic patients with sepsis syndrome, to determine the effects of colloid volume infusion using 10% pentastarch on abnormal gastric tonometer measurements (gastric intramucosal CO2 tension, gastric intramucosal-arterial PCO2 gradient, and gastric intramucosal pH [pHi]) and on cardiac index, global oxygen delivery, and hemoglobin.
DESIGN: Prospective prepost intervention study.
SETTING: Tertiary care, university-affiliated 15-bed general systems intensive care unit. PATIENTS: Patients were studied who had sepsis syndrome, who had pulmonary arterial catheters in place, who were hypovolemic (pulmonary arterial occlusion pressure [PAOP] <15 mm Hg), and who had a gastric arterial PCO2 gradient >10 mm Hg.
INTERVENTIONS: Baseline measurements of gastric intramucosal CO2 tension, gastric intramucosal-arterial PCO2 gradient, and pHi, as well as arterial lactate, pulmonary arterial occlusion, central venous and systemic arterial pressures, thermodilution cardiac output, and temperature. Boluses of 500 mL pentastarch were administered to a total of 1,000 mL or until PAOP was >18 mm Hg. Measurements were repeated at 30 mins and 120 mins postinfusion of pentastarch. MAIN
RESULTS: Volume infusion using pentastarch did not change gastric PCO2, gastric-arterial PCO2 gradient, or pHi. Volume expansion with pentastarch significantly increased cardiac index, global oxygen delivery, and PAOP. Administration of pentastarch decreased hemoglobin and arterial lactate at 30 mins but not at 120 mins.
CONCLUSIONS: Volume expansion using a colloidal solution of 10% pentastarch does not change abnormal intramucosal CO2 tension, gastric-arterial PCO2 gradient, or pHi in critically ill hypovolemic patients who have sepsis syndrome despite increasing cardiac index, oxygen delivery, and pulmonary artery occlusion pressure.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10921549     DOI: 10.1097/00003246-200007000-00012

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  7 in total

Review 1.  The impact of fluid therapy on microcirculation and tissue oxygenation in hypovolemic patients: a review.

Authors:  Joachim Boldt; Can Ince
Journal:  Intensive Care Med       Date:  2010-05-26       Impact factor: 17.440

2.  Methods of monitoring shock.

Authors:  Ednan K Bajwa; Atul Malhotra; B Taylor Thompson
Journal:  Semin Respir Crit Care Med       Date:  2004-12       Impact factor: 3.119

3.  Effects of fluid challenge on gastric mucosal PCO2 in septic patients.

Authors:  Eliézer Silva; Daniel De Backer; Jacques Creteur; Jean-Louis Vincent
Journal:  Intensive Care Med       Date:  2004-01-13       Impact factor: 17.440

4.  Increased blood flow prevents intramucosal acidosis in sheep endotoxemia: a controlled study.

Authors:  Arnaldo Dubin; Gastón Murias; Bernardo Maskin; Mario O Pozo; Juan P Sottile; Marcelo Barán; Vanina S Kanoore Edul; Héctor S Canales; Julio C Badie; Graciela Etcheverry; Elisa Estenssoro
Journal:  Crit Care       Date:  2005-01-11       Impact factor: 9.097

5.  Red blood cell transfusion does not increase oxygen consumption in critically ill septic patients.

Authors:  C J Fernandes; N Akamine; F V De Marco; J A De Souza; S Lagudis; E Knobel
Journal:  Crit Care       Date:  2001-11-01       Impact factor: 9.097

Review 6.  Clinical review: influence of vasoactive and other therapies on intestinal and hepatic circulations in patients with septic shock.

Authors:  Pierre Asfar; Daniel De Backer; Andreas Meier-Hellmann; Peter Radermacher; Samir G Sakka
Journal:  Crit Care       Date:  2003-12-29       Impact factor: 9.097

Review 7.  Pro/con clinical debate: Hydroxyethylstarches should be avoided in septic patients.

Authors:  Frédérique Schortgen; Laurent Brochard; Ellen Burnham; Greg S Martin
Journal:  Crit Care       Date:  2003-02-19       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.